In contrast, DXd demonstrated limited activity in patients with HER2-low colorectal cancer in the DESTINY-CRC01 trial, with no objective response observed among 25 treated patients and a median progression-free survival duration of 1.4 months [41]. This evidence concerns the gene ERBB2 and colorectal cancer.